Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and

Bihl, Florian K; Loggi, Elisabetta; Chisholm, John V; Hewitt, Hannah S; Henry, Leah M; Linde, Caitlyn; Suscovich, Todd J; Wong, Johnson T; Frahm, Nicole; Andreone, Pietro; Brander, Christian

doi:10.1186/1479-5876-3-20

Table 2 Optimal HIV-derived HLA class I restricted CTL epitopes

From: Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and "RecycleSpot"

Protein	HLA Restriction	Sequence	Position
gp120	A02	RGPGRAFVTI	311–320
gp120	A03	TVYYGVPVWK	37–46
gp120	A11l	SVITQACPK	199–207
gp120	A24	LFCASDAKAY	53–62
gp120	A29	SFEPIPIHY	209–217
gp120	A30	HIGPGRAFY	310–318
gp120	A32	RIKQIINMW	419–427
gp120	B07	RPNNNTRKSI	303–312
gp120	B08	RVKEKYQHL	2–10
gp120	B1516/Cw04	SFNCGGEFF	379–387
gp120	B3801	MHEDIISLW	104–112
gp120	B35	VPVWKEATTTL	42–52
gp120	B35	DPNPQEVVL	77–85
gp120	B44	AENLWVTVY	30–38
gp120	B51	LPCRIKQII	416–424
gp120	B55	VPVWKEATTT	42–51
gp120	A33	VFAVLSIVNR	187–196
gp120	A33	EVAQRAYR	320–327
gp41	A01	RRGWEVLKY	787–795
gp41	A02	SLLNATDIAV	818–827
gp41	A0205	RIRQGLERA	335–343
gp41	A03/A30	RLRDLLLIVTR	775–785
gp41	A23/A24	RYLKDQQLL	591–598
gp41	A30	IVNRNRQGY	704–712
gp41	A30	KYCWNLLQY	794–802
gp41	A6802	IVTRIVELL	782–790
gp41	B07	IPRRIRQGL	843–851
gp41	B08	YLKDQQLL	591–598
gp41	B08	RQGLERALL	848–856
gp41	B14	ERYLKDQQL	589–597
gp41	B2705	GRRGWEALKY	791–799
gp41	B35	TAVPWNASW	611–619
gp41	B4001	QELKNSAVSL	810–819
gp41	Cw3/Cw15	RAIEAQQHL	46–54
p17	A02	SLYNTVATL	77–85
p17	A03	KIRLRPGGK	18–26
p17	A03	RLRPGGKKK	20–28
p17	A03	RLRPGGKKKY	20–29
p17	A11	TLYCVHQRI	84–92
p17	A24	KYKLKHIVW	28–36
p17	A30	RSLYNTVATLY	74–86
p17	B08	GGKKKYKL	24–31
p17	B08	ELRSLYNTV	74–82
p17	B2705	IRLRPGGKK	19–27
p17	B35	WASRELERF	36–44
p17	B35	NSSKVSQNY	124–132
p17	B4001	IEIKDTKEAL	92–101
p17	B4002	GELDRWEKI	11–19
p24	A0207	YVDRFYKTL	164–172
p24	A11	ACQGVGGPGHK	349–359
p24	A24/B44	RDYVDRFFKTL	296–306
p24	A25	QAISPRTLNAW	145–155
p24	B07	SPRTLNAWV	148–156
p24	B07/B42/B81/Cw8	TPQDLNTML	48–56
p24	B07	GPGHKARVL	223–231
p24	B07	HPVHAGPIA	84–92
p24	B08	EIYKRWII	260–267
p24	B08	DCKTILKAL	329–337
p24	B14	DRFYKTLRA	298–306
p24	B1501	GLNKIVRMY	267–277
p24	B18	FRDYVDRFYK	293–302
p24	B2703	RRWIQLGLQK	260–269
p24	B2705	KRWIILGLNK	265–274
p24	B35	NPVPVGNIY	245–253
p24	B35	PPIPVGDIY	254–262
p24	B39	GHQAAMQML	193–201
p24	B4001	SEGATPQDL	176–184
p24	B4002	KETINEEAA	70–78
p24	B4002	AEWDRVHPV	78–86
p24	B44	AEQASQDVKNW	174–184
p24	B44	EEKAFSPEV	28–36
p24	B52	RMYSPTSI	143–150
p24	B53	TPYDINQML	48–56
p24	B53/B57	QASQEVKNW	176–184
p24	B57	ISPRTLNAW	15–23
p24	B57	KAFSPEVIPMF	30–40
p24	B57	TSTLQEQIGW	108–118
p24	B57	KAFSPEVI	30–37
p24	B58	TSTLQEQIGW	108–117
p24	B58	TSTVEEQIQW	108–117
p24	Cw0I	VIPMFSAL	36–43
p24	A25	ETINEEAAEW	71–80
p24	A26	EVIPMFSAL	35–43
p15	A02	FLGKIWPSYK	1–10
p15	B14	CRAPRKKGC	42–50
p15	B4001	KELYPLTSL	33–41
p15	B4002	TERQANFL	64–71
Protease	A6802/A74	ITLWQRPLV	3–11
Protease	A6802	DTVLEEMNL	30–38
Integrase	A30	KIQNFRVYY	219–227
Integrase	A03/A11	AVFIHNFKRK	179–188
Integrase	B1503	RKAKIIRDY	263–271
Integrase	B42	VPRRKAKII	260–268
Integrase	B57	KTAVQMAVF	173–181
RT	A26	ETKLGKAGY	604–612
RT	A02	ALVEICTEM	33–41
RT	A02	VIYQYMDDL	179–187
RT	A02	ILKEPVHGV	309–317
RT	A03	ALVEICTEMEK	33–43
RT	A03	GIPHPAGLK	93–101
RT	A03/A1 1	AIFQSSMTK	158–166
RT	A03	QIYPGIKVR	269–277
RT	A03	KLVDFRELNK	73–82
RT	A03	RMRGAHTNDVK	356–366
RT	A11	IYQEPFKNLK	341–350
RT	A11	QIIEQLIKK	80–88
RT	B51	TAFTIPSI	128–135
RT	B57	IVLPEKDSW	244–252
RT	B58	IAMESIVIW	375–383
RT	B81	LFLDGIDKA	715–723
RT	B1503	VTDSQYALGI	651–660
RT	A30	KQNPDIVIY	173–181
RT	A30	KLNWASQIY	263–271
RT	A30	RMRGAHTNDV	356–365
RT	A32	PIQKETWETW	392–401
RT	B08	GPKVKQWPL	18–26
RT	B1501	LVGKLNWASQIY	260–271
RT	B1501	IKLEPVHGVY	309–318
RT	B35	TVLDVGDAY	107–115
RT	B35	VPLDEDFRKY	118–127
RT	B35	NPDIVIYQY	175–183
RT	B35	HPDIVIYQY	175–183
RT	B4001	IEELRQHLL	202–210
RT	B42	YPGIKVRQL	271–279
RT	B51	EKEGKISKI	42–50
Vpr	A02	AIIRILQQL	59–67
Vpr	B07/B81	FPRIWLHGL	34–42
Vpr	B51	EAVRHFPRI	29–37
Vpr	B57	AVRHFPRIW	30–38
Tat	A6801	ITKGLGISYGR	39–49
Tat	B1503	FQTKGLGISY	38–47
Tat	B53	EPVDPRLEPW	2–11
Tat	Cw12	CCFHCQVC	30–37
Vif	A03	RIRTWKSLVK	17–26
Vif	A03	HMYISKKAK	28–36
Vif	A03	KTKPPLPSVKK	158–168
Vif	B07	HPRVSSEVHI	48–57
Vif	B18	LADQLIHLHY	102–111
Vif	B57	ISKKAKGWF	31–39
Nef	A02	PLTFGWCYKL	136–145
Nef	A02	VLEWRFDSRL	180–189
Nef	A03/A11	QVPLRPMTYK	73–82
Nef	A03/A11	AVDLSHFLK	84–92
Nef	A11	PLRPMTYK	75–82
Nef	A24	RYPLTFGW	134–141
Nef	A33	TRYPLTFGW	133–141
Nef	B07	FPVTPQVPLR	68–77
Nef	B07	FPVTPQVPL	68–76
Nef	B07	TPQVPLRPM	71–79
Nef	B07	RPMTYKAAL	77–85
Nef	B07	TPGPGVRYPL	128–137
Nef	B07	RQDILDLWIY	106–115
Nef	B08	WPTVRERM	13–20
Nef	B08	FLKEKGGL	90–97
Nef	B1501	TQGYFPDWQNY	117–127
Nef	B1501	RMRRAEPAA	19–27
Nef	B1503	WRFDSRLAF	183–191
Nef	B18/B53	YPLTFGWCY	135–143
Nef	B2705	RRQDILDLWI	105–114
Nef	B35	VPLRPMTY	74–81
Nef	A01/A29/837/857	YFPDWQNYT	120–128
Nef	B40	KEKGGLEGL	92–100
Nef	B42	TPGPGVRYPL	128–137
Nef	B53	YPLTFGWCF	135–143
Nef	B57	HTQGYFPDWQ	116–125
Nef	B57	HTQGYFPDW	116–124
Nef	Cw07	RRQDILDLWIY	105–115
Nef	Cw7	KRQEILDLWVY	105–115
Nef	Cw8	AAVDLSHFL	83–91
Rev	A03	ERILSTYLGR	57–66
Rev	B57/B58	KAVRLIKFLY	14–23
Rev	Cw05	SAEPVPLQL	67–75
Vpu	A33	EYRKILRQR	29–37

All epitopes were referred from the Los Alamos HIV Immunology Database 2004 [24].

Back to article page

ISSN: 1479-5876

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com

Journal of Translational Medicine

Contact us